The 16th EMIG Business Development meeting took place on the 5th December at the Manor, Weston on the Green. After a networking lunch and a chairman’s welcome from Andrew SM Dean sessions kicked off with Biocodex’s Vice president of business development giving a fascinating presentation on the French group and their international expansion. Nick Craig, associate director of Finance presented an update on Actavis and their specialty brand division Warner Chilcott. In an interesting diversion, Justin Block a bespoke tailor, presented on correct attire and the art of a good suit. This session prompted lively discussion. After a long networking break Datapharm’s CEO Larry Berry and Executive Director Mike Delaney presented on their novel i4Health platform which assists industry in interrogating and making sense of the myriad of NHS data available. Prior to the meeting past delegates were surveyed on the quality and future direction of these meetings. Andrew Dean, presented the results, which were generally very positive. Delegates were then invited to offer further suggestions, following reflection of the data and their experiences. A number of suggestions were carried and will be incorporated into the 2014 meetings. Finally Leslie Galloway updated the group on the latest PPRS. The day ended with a relaxed dinner and quality networking continued. 2014 dates will be published soon. Presentations are available for download from http://www.presentvalueltd.com/emig-bd/
The 15th EMIG Business development group meeting took place at the Manor at Weston on the Green on the 3rd October 2013.
The day kicked off with Guy Clark presenting the Amdipharm Mercury Company and their growth trajectory with Cinven. Colin Love then presented the importance of alliance management in the context of AMCo’s Fucithalmic acquisition. Daiichi Sankyo was showcased by Lak Sahota and Stuart Richards of Pinsent Masons examined new aspects of competition law.
Leslie Galloway updated the group on Value based pricing and the imminent changes expected. The sessions ended with lively descriptions of the roller coaster MBO process by David Trevor and Jim Keeling. The meeting was very well attended with good networking opportunities at lunch, coffee and dinner. The next event will take place on 5th December 2013.
The 13th EMIG Business development group meeting took place at the Manor at Weston on the Green on the 21st March 2013.
The meeting now has an enhanced format with dual presentations from Pharma companies and Specialist service providers. This took the form of real world business scenario’s where both companies presented on best practice and solutions implemented. Topics included understanding parallel trade, getting the most out of BioEurope and how to navigate an SMC submission.
Lundbeck, Present Value, Warner Chilcott, Nordic Pharma, Roboleo and Clarity Pharma presented.
Other companies showcased were Teva UK Limited and the new team at Pinsent Masons.
Finally Leslie Galloway presented the latest VBP position and EMIG’s view.
The meeting was oversubscribed with lively networking at lunch, coffee and dinner.
The next event will take place on June 20th.
The 12th EMIG BD meeting was held on the 6th December 2012 at the Manor, Weston Green, Oxfordshire.
The meeting was well attended with a good mix of delegates from entrepreneurial speciality to global Pharma.
Veeva systems’ Nate Gazaway presented on the changing landscape of Pharmaceutical commerce and how their CRM system can help draw together the myriad of ways the industry is now communicating with healthcare professionals. Viropharma’s Rebecca Jary then showed the group how the system had assisted across multiple product launches in several EU territories.
Charles Joynson introduced his brand new data analysis tool Scriptmap with a very generous discount available for EMIG members. Scriptmap makes sense and utility out of the PCT prescribing data now being offered by the NHS.
Corbett Keeling then updated the group with their latest view on fundraising and deal flow.
After a generous networking break James Brodie introduced GW Pharmaceuticals. This was a fascinating and expansive presentation on the medicinal use of the Cannabinoid Platform.
Andrew Dean of Present Value then presented the feedback of our membership survey on the direction of the group in 2013, this was followed by a lively discussion on how we can make this valuable meeting even better in the future.
Finally Leslie Galloway brought us all up to date on value based pricing and its progress through government.
The day finished with a delicious networking dinner and the wine flowed until the early hours.
Present Value Limited a Business Development Company serving the needs of the Pharmaceutical and Chemical Industries, is pleased to announce that it has sold the rights in the UK and selected territories worldwide for Rozalex to Hughen Limited.
Rozalex which is a range of barrier creams, skin cleansers and reconditioning creams, is used in the workplace for the protection and cleansing of normal skin to reduce the incidence of occupational dermatitis.
The brand since its acquisition from Johnson Diversey in 2008 has been extensively developed at Present Value, receiving a thorough brand makeover with the introduction of new lines and innovative products.
Andrew SM Dean director of Present Value commented: “ I wish Hughen Limited the absolute best in developing the brand further, Rozalex is now in the right hands for its continued success”
For Product related information:
Rozalex Limited 0844 811 1250